AUS
NZ
UK
CA
USA
IND
Highlights
AbbVie Inc. has seen strong stock performance, outpacing both the broader market and sector indexes.
The company reported better-than-expected Q3 earnings, driven by strong sales of immunology drugs Rinvoq and Skyrizi.
AbbVie’s positive earnings history and analyst sentiment signal confidence in future growth prospects.
AbbVie Inc. (NYSE:ABBV), headquartered in North Chicago, Illinois, has established itself as a major player in the global healthcare sector. With a market capitalization of $356.2 billion, the company is known for its innovative therapies in immunology, oncology, neuroscience, aesthetics, and eye care.
Over the past year, AbbVie’s stock has performed notably well, rising 42.5% over the last 52 weeks, surpassing the broader S&P 500 Index, which gained 35.8% during the same period. In 2024, AbbVie’s share price increased by nearly 30%, outperforming the Health Care Select Sector SPDR Fund (XLV), which gained 15.4% over the past year.
AbbVie’s recent performance has further reinforced its market strength. In its Q3 earnings report on October 30, the company announced adjusted earnings per share (EPS) of $3, exceeding expectations, and revenue of $14.5 billion. The robust performance was fueled by significant growth in its immunology segment, with strong sales from its drugs Rinvoq and Skyrizi, which saw year-over-year sales increases of 47.4% and 51.5%, respectively. AbbVie also raised its full-year EPS guidance, reflecting confidence in its continued growth trajectory.
Despite analysts forecasting a slight 1.4% decline in EPS for the current fiscal year, AbbVie has consistently exceeded consensus estimates, a track record that bolsters investor confidence. Among the 25 analysts covering AbbVie, the stock currently carries a “Moderate Buy” consensus, with 15 analysts giving a “Strong Buy” rating. This marks an improvement from three months ago, when there were fewer “Strong Buy” recommendations.
Following AbbVie’s strong Q3 results, Guggenheim analyst Vamil Divan raised the company’s price projection to $221, signaling optimism about AbbVie’s ongoing performance and future potential.
